What Personalized Stem Cells does

Personalized Stem Cells, Inc. (PSC) is a privately held biotechnology company founded in 2018 in Poway, California, that operates an FDA-inspected, cGMP-certified laboratory dedicated to autologous adipose-derived stem cell (ASC) banking and therapy. The company isolates mesenchymal stem cells (MSCs) from a patient's own adipose tissue via minimally invasive lipoaspiration, culture-expands them over approximately 60 days into pharmaceutical-grade doses, and cryopreserves the resulting master cell bank at -196C for long-term storage. PSC holds an FDA IND for use of autologous ASCs in knee osteoarthritis (granted July 2019) and ran a Phase 1/2a trial in which 79.3% of patients improved above the minimal important change and 78% avoided joint replacement at 2.6 years follow-up; the company additionally secured an emergency IND for COVID-19 ARDS in 2020 and licenses technology from its sister company VetStem, which has treated over 17,000 veterinary patients. PSC monetizes through a three-tier membership program — StemPreserve (fat-tissue banking starting at $2,500 plus annual storage), StemReady (expanded, treatment-ready cells starting at $12,500), and StemInsure (annual family membership) — all delivered on a private-pay basis since the therapies are not covered by insurance. Distribution is handled through a domestic network of 30+ board-certified affiliate physicians across 13 U.S. states, supplemented by direct-to-consumer marketing (educational content, SEO, complimentary consultations via a patient concierge), with additional access through FDA Compassionate Use and Federal Right-to-Try pathways. PSC's leadership includes Dr. Bob Harman (CEO & Founder, 20+ years of stem cell innovation via VetStem), Dr. Chris Rogers (CMO, orthopedic surgeon), Dr. Peter Hanson (Medical Director), Dr. Jaime Garza (Medical Director, Sports Division, appointed Senior Strategic Advisor in November 2025), and Dr. Thomas Adamson (Rheumatologist & Clinical Research Advisor).

Name

Personalized Stem Cells

Legal name

Personalized Stem Cells, Inc.

Website

https://personalizedstemcells.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Personalized Stem Cells is a privately held San Diego biotech that isolates, culture-expands, and cryopreserves autologous adipose-derived stem cells in an FDA-inspected cGMP lab, delivering stem cell banking and treatment services through a 30+ physician network across 13 U.S. states to patients seeking alternatives to joint replacement and other invasive surgeries.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Stem Cell Banking Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Autologous) (HLAAABAA), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

• Stem cell banking
• Autologous stem cell therapy
• Adipose-derived stem cells
• Regenerative medicine services
• Cell therapy processing

Headquarters

HQ city

Poway

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. StemPreserve Membership: Fat tissue banking service where stem cells are collected, processed, and cryogenically stored for future expansion and use. Customers pay an initial fee plus annual storage membership.
2. StemReady Treatment: Premium service including fat tissue collection, culture expansion of stem cells to pharmaceutical-grade doses (targeting 12 million cells), safety testing, and cryopreservation for immediate or near-term therapeutic use.
3. StemInsure Family Membership: Annual family membership program for long-term cellular readiness, providing biological insurance for multiple family members with continued access to cell banking and treatment services.
4. Physician Network Services: Revenue from training and certifying affiliated physicians in PSC's FDA-compliant protocols and treatment pathways, supporting clinical trial enrollment and Right-to-Try treatments.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Personalized Stem Cells (PSC) provides autologous adipose-derived stem cell banking, culture expansion, and cryopreservation services through its FDA-inspected cGMP laboratory in Poway, California. The company collects patients' own fat tissue via a minimally invasive mini-lipoaspiration procedure, isolates and culture-expands mesenchymal stem cells (MSCs) to pharmaceutical-grade doses (targeting 12 million cells), and cryopreserves them in a master cell bank for future physician-directed therapeutic use. Patients access cells through clinical trials, the Federal Right-to-Try Act, or FDA Compassionate Use pathways.

Product overview

Personalized Stem Cells offers a three-tier stem cell banking membership program centered around StemInsure™, StemReady™, and StemPreserve™. StemPreserve™ provides initial fat-tissue collection and cryopreservation; StemReady™ involves 60-day culture expansion and safety testing to produce pharmaceutical-grade stem cell doses for immediate therapeutic use; StemInsure™ is the overarching annual family membership for long-term cellular readiness. Treatment access is provided through clinical trials (planned for 2026), FDA Compassionate Use, and the Federal Right-to-Try Act pathway.

Differentiator

Problem solved

Functional benefit

Brands

• StemInsure: Annual membership program for families providing long-term cellular readiness and biological insurance through stem cell storage.
• StemReady
• StemPreserve

Products and services

• StemPreserve™

Quantifiable outcome

• 79.3% of patients improved above minimal important change (MIC) with average improvement 2.2x MIC in knee osteoarthritis trial
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered supporting and core.

• Sorrento TherapeuticssupportingTechnology or Integration · 30 March 2020PSC licensed technology to Sorrento Therapeutics in April 2020 as part of COVID-19 response efforts, applying stem cell therapy expertise to treat hospitalized patients.
• San Diego Zoo Wildlife AlliancesupportingStrategic or Co-development PartnerCollaboration supporting the One Medicine/One Health concept connecting human and veterinary medicine. The San Diego Zoo Wildlife Alliance logo appears on PSC materials indicating partnership in regenerative medicine research and education.
• VetStemcoreStrategic or Co-development PartnerSister company and parent organization providing 17,000+ veterinary patient clinical data that informed PSC's human cell therapy development. VetStem pioneered stem cell therapies in dogs and horses, with FDA-reviewed products. Shared intellectual property portfolio and regulatory expertise.
• San Diego ZoosupportingStrategic or Co-development PartnerPartnership supporting One Medicine approach connecting veterinary and human regenerative medicine, with shared research methodologies and treatment strategies.
• DataBiologicssupportingStrategic or Co-development PartnerHealthcare data collaboration supporting regenerative medicine research and patient outcome tracking. Logo appears on PSC materials indicating partnership.
• Orthohealing CentersupportingChannel Partner/ Reseller/ DistributorLos Angeles-based regenerative medicine practice affiliated with PSC network, offering stem cell treatments to patients using PSC's FDA-compliant cell processing. Multiple physicians from this practice appear in PSC's physician affiliate listings.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Organogenesis Holdings: Organogenesis is a publicly-traded regenerative medicine company specializing in wound care and surgical biologics. Comparable as a broader incumbent in commercial-stage regenerative medicine, though focused on skin/wound indications rather than autologous cell therapy.
• MiMedx Group: MiMedx is an established publicly-traded regenerative medicine company offering placental tissue allografts for wound care and surgical recovery. It competes in the broader regenerative medicine category with PSC but focuses on different tissue types and indications.

Emerging players

• Cryo-Cell International: Cryo-Cell is a U.S. cell banking company focused on cord blood and menstrual blood-derived stem cell banking. Comparable to PSC's StemPreserve/StemInsure banking subscription business, though in different tissue sources.

Direct peers

• VetStem Biopharma: VetStem is PSC's sister company pioneering autologous adipose-derived stem cell therapy in dogs and horses. While not a direct commercial competitor, it shares identical core technology (ASC isolation, expansion, banking) and is the closest technological and operational analog to PSC.
• BrainStorm Cell Therapeutics: BrainStorm is developing NurOwn, an autologous MSC-based therapy for neurodegenerative diseases. It is comparable to PSC as a small-cap autologous stem cell therapy developer pursuing FDA-regulated pathways.
• Mesoblast: Mesoblast develops mesenchymal stem cell (MSC) therapies, including remestemcel-L for inflammatory conditions. It is highly comparable to PSC as a clinical-stage MSC developer pursuing regenerative indications under FDA pathways.
• Vericel Corporation: Vericel develops and commercializes autologous cell therapies, including MACI for cartilage repair of the knee — a directly comparable autologous cell therapy targeting the same orthopedic regenerative medicine use case as PSC.
• Caladrius Biosciences: Caladrius develops autologous cell therapies for cardiovascular and immune-mediated diseases. Comparable to PSC in size, modality (autologous cell therapy), and clinical-stage posture.
• Pluristem Therapeutics: Pluristem develops placenta-derived cell therapies for inflammatory and ischemic conditions. It is comparable to PSC as a small-cap cell therapy developer pursuing regenerative and inflammatory indications through clinical trials.
• BioRestorative Therapies: BioRestorative develops autologous stem cell therapies (e.g., BRTX-100 for disc disease) and pursues FDA-regulated clinical pathways — closely comparable to PSC's autologous MSC clinical approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Personalized Stem Cells